Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plc

abrdn plc lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 30.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 431,098 shares of the biotechnology company's stock after purchasing an additional 101,253 shares during the period. abrdn plc owned about 0.46% of Sarepta Therapeutics worth $53,935,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after buying an additional 75 shares during the period. EP Wealth Advisors LLC grew its holdings in Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company's stock worth $774,000 after acquiring an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Sarepta Therapeutics by 1.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company's stock valued at $1,000,000 after purchasing an additional 120 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Sarepta Therapeutics by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company's stock worth $134,000 after purchasing an additional 155 shares during the last quarter. Finally, Innealta Capital LLC acquired a new stake in Sarepta Therapeutics in the second quarter valued at $31,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The stock was bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company's stock, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $2.43 during midday trading on Wednesday, reaching $127.78. The stock had a trading volume of 658,047 shares, compared to its average volume of 1,233,185. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The stock has a market cap of $12.08 billion, a P/E ratio of 1,161.64 and a beta of 0.82. The firm has a fifty day simple moving average of $128.07 and a two-hundred day simple moving average of $132.57. Sarepta Therapeutics, Inc. has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the firm earned ($0.27) earnings per share. The firm's revenue was up 38.9% compared to the same quarter last year. On average, equities analysts expect that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current year.

Analyst Upgrades and Downgrades

SRPT has been the subject of several analyst reports. Piper Sandler lowered their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Citigroup dropped their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. UBS Group raised their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a report on Tuesday, September 17th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 target price on the stock. Finally, Evercore ISI upgraded shares of Sarepta Therapeutics from an "in-line" rating to an "outperform" rating and cut their price target for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $182.95.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.